On August 4, 2026, the 20th Frost & Sullivan Global Growth, Innovation and Leadership Summit and the 5th New Investment Conference were grandly opened at The Shangri-La Hotel in Jing'an, Shanghai. The 65th anniversary of Frost & Sullivan Global and the 20th anniversary of the Frost & Sullivan Summit were celebrated during a dinner event on the evening of August 4, and the 2026 Frost & Sullivan Global Award and China Award were announced at the event.
Based on recent research and analysis of the global large-molecule new drug technology market, as well as studies and evaluations of related companies in the industry, Frost & Sullivan awarded JAHUA BIOTECHNOLOGY (Qingdao) Co., Ltd. ('Jahua Bio') the 2026 Frost & Sullivan Global Large-Molecule New Drug Technology Innovation Leadership Award. Aroop Zutshi, President and Managing Partner of Frost & Sullivan and Executive Director of the Global Board of Directors, and Meng Yi, Chair of the Frost & Sullivan Growth Strategy Expert Committee, former General Manager and Vice Chairman of HSBC Global Banking China, presented the award to Mr. Liu Longbin, Founder and CEO of JAHUA BIOTECHNOLOGY (Qingdao) Co., Ltd.
Frost & Sullivan Global President and Managing Partner, Global Board Executive Aroop Zutshi, and Chairman of the Frost & Sullivan Growth Strategy Expert Committee, former HSBC Global Banking China Regional General Manager and Vice Chairman Meng Yi, presented the award to JAHW Biotech (Qingdao) Co., Ltd.
Jiehua Biotech is an innovative company in the field of large-molecule new drugs.
Jiehua Biotechnology (Qingdao) Co., Ltd. was established in 2008 and is located in Qingdao, Shandong. It is a high-tech biopharmaceutical company focused on the research, development, production, and sales of new biological drugs for treating major human diseases. Adhering to the principle of "focusing solely on original new drugs," the company utilizes its self-developed gene engineering technology platform to develop three new biological drugs with independent intellectual property rights: Novaferon, Nova-EPO, and Nova-GM-CSF. The company has obtained over 100 invention patents from major countries such as the United States, the European Union, China, and Japan. Positioned at the forefront of bio-molecular drug research with a new structure, the company aims to become an internationally competitive innovator in large molecule new drug technology.
With over twenty years of R&D experience, the original biological new drug "LeFuNeng" has entered clinical application.
Frost & Sullivan's core product "LeFuNeng", developed over many years,Reorganizing Cytokine Gene-Derived Protein Injection），于2018年4月获得国家药品监督管理局颁发的国家1类生物新药证书（国药证字S20180001）和药品注册批件（国药准字S20180002）。据公开资料显示，"乐复能"是山东省多年来首个获批的国家一类新药，也是青岛首个获批的国家一类新药。该药物属于核苷类抗病毒药物和人干扰素药物之外的又一治疗乙肝的药物类别。临床数据显示，传统核苷类似物或干扰素治疗1年左右，约30%病人可实现乙肝病毒复制的抑制；而"乐复能"在3个月、6个月、9个月的治疗节点上，分别观察到约30%、40%、50%的疗效。经国家药品生物制品检定院检测验证，乐复能在抗肿瘤活性方面较同类蛋白质药物有显著提高，抗病毒活性亦显示出一定优势。2009年，"乐复能"被科技部列入国家"重大新药创制"专项。
蛋白质工程技术平台支撑后续产品管线，全球化布局初步形成
杰华生物经过多年研究积累，建立了"基因改造高活性蛋白质"和"蛋白质长效化"两大具有自主知识产权的核心技术平台。基于这些平台，公司在"乐复能"之后相继研发了另外两个大分子蛋白质新药——第三代长效促红细胞生成素Nova-EPO和第三代长效人粒/巨噬细胞集落刺激因子Nova-GM-CSF。三个生物新药均已申请并获得美国、欧盟、中国、日本等主要国家发明专利。公司已构建起集研发、规模化生产与销售于一体的全球化战略布局，业务运营覆盖青岛、北京、香港、北美及日本等核心地区。
以临床价值与品牌实力赢得行业认可
杰华生物以扎实的临床数据与差异化的管线布局，持续赢得行业与资本市场的认可。2018年，公司被认定为山东省首家硬科技独角兽企业、中国原创生物新药领域具有代表性的独角兽企业。面向未来，杰华生物将继续推进原创生物新药的研发与商业化，深耕大分子创新药领域。
Regarding Frost & Sullivan Frost & Sullivan Innovation Technology Leadership Award
Frost & Sullivan Global Technology Innovation Leadership Award recognizes the outstanding performance and exceptional achievements of companies in areas such as technology innovation, market potential, customer service, and brand development. The Frost & Sullivan team identified competitive top companies through in-depth interviews, industry analysis, and secondary research. The independent judging panel, composed of third-party investment and financing experts, financial professionals, bankers, and renowned listed entrepreneurs, conducted a rigorous evaluation of the companies nominated by Frost & Sullivan and decided to award the '2026 Frost & Sullivan Global Large-Molecule New Drug Technology Innovation Leadership Award' to Jinhua Biotech (Qingdao) Co., Ltd.
